Maxgalip AT Tablet contains a combination of Amitriptyline 10 mg and Pregabalin 75 mg, formulated for the management of neuropathic pain and certain mood disorders. Amitriptyline, a tricyclic antidepressant, acts by inhibiting the reuptake of norepinephrine and serotonin, thereby modulating pain perception and exerting antidepressant effects. Pregabalin, an anticonvulsant and analgesic agent, binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing neurotransmitter release and diminishing neuronal excitability. This synergistic combination is indicated for conditions such as diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and generalized anxiety disorder where both pain relief and mood stabilization are required. Maxgalip AT Tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on therapeutic response and tolerability. Common adverse effects may include dizziness, somnolence, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiac disorders, renal impairment, or those taking other central nervous system depressants. Regular monitoring and adherence to prescribed regimens are essential to optimize therapeutic outcomes and minimize risks. This medication is contraindicated in individuals with hypersensitivity to its components or a history of monoamine oxidase inhibitor use within 14 days.